Randomised phase 3 study of ivosidenib in IDH1-mutant chemotherapy-refractory cholangiocarcinoma

Juan Valle, et al.

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

1 results
- Title(descending)

Improved treatment option for patients with previously treated IDH-1 mutated cholangiocarcinoma (bile duct cancer) (Ivosidenib)
Valle, J. (Corresponding participant)
Impact: Health and wellbeing